SCHEMBL15568656

SCHEMBL15568656

Cc1ccc(CS(=O)(=O)CCO)cc1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.66
POLB P06746 2/20 0.54
ALDH1A1 P00352 2/20 0.50
CYP2C19 P33261 3/20 0.48
TP53 P04637 1/20 0.46
CYP3A4 P08684 5/20 0.46
CYP2D6 P10635 2/20 0.46
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
RAB9A P51151 1/20 0.45
LMNA P02545 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9574362 0.89 KMT2A (0.50) KMT2APOLBALDH1A1CYP2C19TP53
SCHEMBL15568595 0.89 KMT2A (0.62) KMT2APOLBALDH1A1CYP2C19TP53
SCHEMBL4400952 0.83 KMT2A (0.62) KMT2APOLBALDH1A1CYP2C19TP53
SCHEMBL14426922 0.82 KMT2A (0.62) KMT2APOLBALDH1A1CYP2C19TP53
SCHEMBL1202589 0.80 RECQL (0.46) KMT2APOLBALDH1A1CYP3A4CYP2D6
SCHEMBL15568723 0.80 KMT2A (0.43) KMT2APOLBCA1CA2CA9
SCHEMBL15568647 0.80 USP2 (0.44) KMT2APOLBALDH1A1CYP2C19TP53
SCHEMBL13870211 0.79 KMT2A (1.00) KMT2APOLBALDH1A1CYP2C19TP53
SCHEMBL10482000 0.79 CA1 (0.50) KMT2APOLBALDH1A1CA1CA2
SCHEMBL10289671 0.79 KMT2A (0.58) KMT2APOLBALDH1A1CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882727-B1 IMMUNOMODULATORY COMPOUNDS UNIV STRATHCLYDE (GB) 2021-01-20 EP disclosed
EP-2882727-B1 IMMUNOMODULATORY COMPOUNDS UNIV STRATHCLYDE (GB) 2021-01-20 EP disclosed
US-9598386-B2 Immunomodulatory compounds UNIVERSITY OF STRATHCLYDE (GB) 2017-03-21 US disclosed
US-9598386-B2 Immunomodulatory compounds UNIVERSITY OF STRATHCLYDE (GB) 2017-03-21 US disclosed
US-9598386-B2 Immunomodulatory compounds UNIVERSITY OF STRATHCLYDE (GB) 2017-03-21 US disclosed
US-20150218116-A1 Immunomodulatory Compounds UNIVERSITY OF STRATHCLYDE (GB) 2015-08-06 US disclosed
US-20150218116-A1 Immunomodulatory Compounds UNIVERSITY OF STRATHCLYDE (GB) 2015-08-06 US disclosed
US-20150218116-A1 Immunomodulatory Compounds UNIVERSITY OF STRATHCLYDE (GB) 2015-08-06 US disclosed
EP-2882727-A1 IMMUNOMODULATORY COMPOUNDS University of Strathclyde (GB) 2015-06-17 EP disclosed
WO-2014023934-A1 IMMUNOMODULATORY COMPOUNDS UNIVERSITY OF STRATHCLYDE (GB) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218116-A1 Immunomodulatory Compounds TSLP, IL2, ICOS KMT2A 3352/4885POLB 3712/4885ALDH1A1 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.